|
Tagrisso (osimertinib) receives US FDA full approval
|
31 March 2017 |
|
Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
|
28 March 2017 |
|
AstraZeneca and Circassia enter strategic collaboration in respiratory disease
|
17 March 2017 |
|
MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897
|
07 March 2017 |
|
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
|
28 February 2017 |
|
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
|
20 February 2017 |
|
Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis
|
16 February 2017 |
|
Symbicort granted paediatric exclusivity in the US
|
26 January 2017 |
|
AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities
|
23 January 2017 |
|
AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer's disease
|
13 January 2017 |